Immune Targeting Systems
Immune Targeting Systems develops synthetic vaccines for mutating viruses, improving the quality of life for those infected by viruses.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Acquisition | ||
| Total Funding | 000k | ||
Related Content
Altimmune is a clinical-stage biopharmaceutical company dedicated to developing advanced treatments for liver disease, chronic Hepatitis B, and cancer, along with intranasal vaccines for infectious diseases such as anthrax, influenza, and COVID-19. The company operates in the biopharmaceutical market, focusing on creating novel therapies that address significant unmet medical needs. Altimmune's business model revolves around research and development, progressing through clinical trials, and eventually seeking regulatory approval for its diverse pipeline of therapeutic candidates. Revenue generation is anticipated through the commercialization of these therapies, either independently or through strategic partnerships and collaborations with other pharmaceutical companies. The primary clients include healthcare providers, hospitals, and patients requiring specialized treatments for the aforementioned conditions. Altimmune's innovative approach and commitment to addressing critical health challenges position it as a key player in the biopharmaceutical industry.
Keywords: biopharmaceutical, liver disease, Hepatitis B, cancer, intranasal vaccines, infectious diseases, clinical-stage, therapeutic candidates, research and development, healthcare.